Ann: Half Year Results Investor Presentation, page-2

Joined the call this morning, but the person directing the questions either ignored the question, or summerised it so it never really got answered.

Just sent an email to them with the following questions; lets hope they respond.

1. The Australian business has over 4000 pharmacies contracted which per the AGM presentation in Nov indicated a market share of 70%; despite this, the business lost ~$2.5m for 1H22. Given the number of pharmacies, the market share, and the number of patients using the app is the pricing for the product appropriate given the loss in the business (and/or is the cost base too high)?

2. The recent contract you signed in New Zealand; will this be earnings accretive (PBT positive) or is this a long term strategy that will require investment before it breaks even?

3. How many pharmacies need to be signed up in the UK before the operation reaches a breakeven

4. There will be a final payment to Adheris due in May (USD 3m); currently you only have ~$5m in cash available. Does the company have sufficient funds to continue operations or will there need to be a capital raise to pay this amount?